BioCentury
ARTICLE | Clinical News

AXL1717: Interim Phase II data

April 8, 2013 7:00 AM UTC

Interim data from the open-label, international Phase II AXL-003 trial in patients with previously treated, locally advanced or metastatic NSCLC showed that twice-daily 400 mg oral AXL1717 for 21 days...